Amazing New Drug Shows Strong Promise for Multiple Tumor Types

Amazing New Drug Shows Strong Promise for Multiple Tumor Types

Recently, BeiGene presented the preliminary findings of an ongoing dose-escalation Phase I study of BGB-A317, a checkpoint inhibitor. The presentation was made at the 2016 Annual Meeting of the American Society of Clinical Oncology in Chicago. BGB-A317, a monoclonal antibody, is designed to bind to PD-1, a receptor on the surface of cells that downregulates… Read More…

What You Need to Know about Cytokines in Immuno-Oncology

What You Need to Know about Cytokines in Immuno-Oncology

One of the main approaches to cancer immunotherapy involves cytokines, which serve as messengers for the immune system. Immune cells secrete cytokines, which are proteins or glycoproteins, to strengthen or suppress normal immune functions. Researchers are attempting to take advantage of this regulatory role to boost the activity of macrophages and natural killer cells, as… Read More…

Immuno-Oncology Research: The Need to Stand Out in the Crowd

Immuno-Oncology Research: The Need to Stand Out in the Crowd

Immuno-oncology has become a central focus for medical research firms and organizations across the country, and many are working on the same targets. Over the past five years, interest in immuno-oncology has spiked dramatically due to real changes in survival curves for many cancers and the extraordinary amount of money being made available. While all… Read More…

CAR T-Cell Therapy: Engineering Your Immune Cells to Fight Cancer

CAR T-Cell Therapy: Engineering Your Immune Cells to Fight Cancer

One of the most important questions that immuno-oncologists will tackle in the coming years is figuring out where chimeric antigen receptor (CAR) T-cell therapy will fit into the larger picture. Academic centers across the country have been using this technology to successfully treat patients, but adapting this complicated system to a community setting introduces a… Read More…

A Look at the Role Monoclonal Antibodies Play in Immuno-Oncology

A Look at the Role Monoclonal Antibodies Play in Immuno-Oncology

Immuno-oncological research is exploring several different approaches to immunotherapy, including vaccines, checkpoint inhibitors, and monoclonal antibodies. At present, several different types of monoclonal antibody drugs exist, but researchers are still exploring how to employ them most effectively in a treatment plan. The term monoclonal antibody refers to a molecule produced in a laboratory that has… Read More…

A Brief Look at the History of Immuno-Oncology

A Brief Look at the History of Immuno-Oncology

In recent years, advances in immuno-oncology have generated a lot of excitement about the future of cancer care. From radical new therapies to combinations with existing approaches, the field is generating a remarkable amount of hope. While the future looks bright, it is important to understand and revisit the history of immuno-oncology, which dates back… Read More…

UCLA Researchers Find Potential Mechanism for Immunotherapy Resistance

UCLA Researchers Find Potential Mechanism for Immunotherapy Resistance

One of the biggest questions in the field of immuno-oncology is the issue of why the treatments work so effectively for some people, yet other patients experience virtually no benefit or experience tumor recurrence after the initial response. Researchers from the University of California, Los Angeles (UCLA) may have made the first step in answering… Read More…

The Parker Foundation Launches Cancer Immunotherapy Institute

Led by Silicon Valley entrepreneur and philanthropist Sean Parker, The Parker Foundation recently announced the launch of the Parker Institute for Cancer Immunotherapy. Following the recent loss of his close friend to cancer, Parker wants to figure out how to battle cancer and has particularly focused on the field of immuno-oncology. The friend whom Parker… Read More…